Trial reportEuropean journal of cancer (Oxford, England : 1990)2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Trial report in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.The Lancet. Child & adolescent health · 2020Guideline
- Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Aspirin in Audiology: A Dual-Edged Sword in Hearing Loss and Its Nanotechnology-Driven Future.Drug design, development and therapy · 2026Review
- Fasudil protects spiral ganglion neurons and hair cells against cisplatin-induced apoptosis by inhibiting reactive oxygen species accumulation and regulating the ROCK/PTEN/AKT signaling pathway.Toxicology research · 2025Article
- Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review.Antioxidants (Basel, Switzerland) · 2024Review
- In Vitro Assessment of Cisplatin/Hyaluronan Complex for Loco-Regional Chemotherapy.International journal of molecular sciences · 2023Article
- The protective effect of aspirin-induced temporary threshold shift in an animal model of cisplatin-related ototoxicity.Journal of cancer research and clinical oncology · 2023Article
- Antioxidant Therapy against Oxidative Damage of the Inner Ear: Protection and Preconditioning.Antioxidants (Basel, Switzerland) · 2020Review
- Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.Expert opinion on drug metabolism & toxicology · 2020Review
- Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer.Cancers · 2020Review
- [Research progress on the relationship between cisplatin ototoxicity and autophagy].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2020Review
- Article
- Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.The Lancet. Child & adolescent health · 2019Review
- Challenges of Hearing Rehabilitation after Radiation and Chemotherapy.Journal of neurological surgery. Part B, Skull base · 2019Article
- Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.Journal of medicinal chemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundCisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common mechanism, involving reactive oxygen species in the inner ear. Aspirin has been shown to minimise gentamicin-induced ototoxicity. We, therefore, tested the hypothesis that aspirin could also reduce ototoxicity from cisplatin-based chemotherapy.
methodsA total of 94 patients receiving cisplatin-based chemotherapy for multiple cancer types were recruited into a phase II, double-blind, placebo-controlled trial and randomised in a ratio of 1:1 to receive aspirin 975 mg tid and omeprazole 20 mg od, or matched placebos from the day before, to 2 days after, their cisplatin dose(s), for each treatment cycle. Patients underwent pure tone audiometry before and at 7 and 90 days after their final cisplatin dose. The primary end-point was combined hearing loss (cHL), the summed hearing loss at 6 kHz and 8 kHz, in both ears.
resultsAlthough aspirin was well tolerated, it did not protect hearing in patients receiving cisplatin (p-value = 0.233, 20% one-sided level of significance). In the aspirin arm, patients demonstrated mean cHL of 49 dB (standard deviation [SD] 61.41) following cisplatin compared with placebo patients who demonstrated mean cHL of 36 dB (SD 50.85). Women had greater average hearing loss than men, and patients treated for head and neck malignancy experienced the greatest cHL.
conclusionsAspirin did not protect from cisplatin-related ototoxicity. Cisplatin and gentamicin may therefore have distinct ototoxic mechanisms, or cisplatin-induced ototoxicity may be refractory to the aspirin regimen used here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.